Effectiveness of an Oral Supplementation of Phycocyanin and Palmitoylethanolamide for a Short-Term Prophylaxis of Menstrual Migraine: A Retrospective Observational Study
Observational studyHumansWith phycocyanin
This study tested palmitoylethanolamide together with phycocyanin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- 61 women with migraine without aura (from 800 records reviewed, 220 screened)
- Dose used in the study
- Two capsules daily of phycocyanin and palmitoylethanolamide, from five days before to five days after menstruation onset
- Duration
- Three consecutive months
- What was measured
- Migraine severity, frequency and duration during the perimenstrual window; analgesic use; migraine-associated symptoms; compared with a three-month period without supplementation.
What the authors reported
This retrospective observational study found:
- Migraine severity fell significantly across all perimenstrual days (p<0.0001).
- Overall monthly attack frequency was unchanged, but perimenstrual migraine days fell from month one (p<0.05).
- Migraine duration fell at one, two and three months.
- Analgesic use and migraine-associated symptoms also fell.
- Treatment was well tolerated.
Limits of this study
A retrospective study with no control group, so it cannot separate the effect of PEA from phycocyanin or from natural fluctuation. Publication costs were supported by Kura Srl; one author was employed by a headache clinic named in the paper.
Source
PubMed 42072406 · doi:10.3390/biomedicines14040865
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.